INTRODUCTION AND OBJECTIVES: Elderly and frail patients are becoming more common in our clinical practice. Currently one of the greatest challenges is balancing the life expectancy of those patients against aggressive treatments that carry significant risks. The aim of our study was to describe complication rates up to 30 days of patients with radical cystectomy with cutaneous ureterostomy diversion (CUD).
METHODS: The study included a large International multicenter cohort (10 centers) of 365 patients undergoing radical cystectomy with CUD for bladder cancer between 2011 and 2017. Demographic, clinical and histological characteristics of all patients were recorded. Indications for CUD were advanced age, single kidney, comorbities and history of multiple bowel surgeries. Perioperative (up to 30 days) complications were recorded according the Clavien Classification System (CCS). High grade complications were defined as CCS ! IIIa.
RESULTS: Median (range) age was 76 (47/89) years. Overall, males were 295/365 (81%) and females 70/365 (19%). The ASA score was: I in 9/365 (2%); II in 102/365 (28%), III in 209/365 (58%) and IV in 42/365 (12%) patients. Median (range) operative time and hospitalization stay were 210 (60/500) min and 14 (2/119) days, respectively. Overall 58 (15%) underwent monolateral ureterostomy and 307 (85%) underwent bilateral ureterostomy. Advance disease(pT!3a) was present in 233 (64%) and positive nodes in 91 (25%) patients. Overall morbidity and mortality rates were 67% and 2% respectively. Lowgrade complications' (CCS II) rate of the series was 80%, anemia requiring transfusion being the most common one (Table I) . High grade complications 'rate was 12% and out of them only 14 cases (34%) required surgical intervention under general anesthesia or advanced life support (CCS !IIIb)
CONCLUSIONS: Cutaneous ureterostomy diversion in patients undergoing radical cystectomy for bladder cancer is a valid surgical option with a high grade Clavien complication rate of 12%. Cutaneous ureterostomy diversion should be considered in patients with aggressive disease and/or poor performance status.
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MP26-11 TEN-YEAR ONCOLOGIC OUTCOMES FOLLOWING ROBOT ASSISTED RADICAL CYSTECTOMY: RESULTS FROM THE INTERNATIONAL ROBOTIC CYSTECTOMY CONSORTIUM
INTRODUCTION AND OBJECTIVES: Radical cystectomy is the gold standard for muscle invasive bladder cancer. Robot-assisted surgery has been accepted as a suitable alternative. Critics of robotassisted radical cystectomy (RARC) have shown consensus regarding long term oncologic outcomes. Multi-institutional, ten-year oncologic outcomes for RARC have not been previously reported.
METHODS: A retrospective review of the prospectively maintained International Robotic Cystectomy Consortium database was performed. At present 7 institutions of 26 in patients who had RARC over 10 years. 240 patients were reviewed for demographics and perioperative outcomes. Kaplan Meier curves were used to model disease specific survival (DSS), recurrence free survival (RFS), and overall survival (OS) (Fig1a, f) . Multivariate Cox regressions models were used to identify predictors.
RESULTS: Mean age was 67AE11 (range 28-90), BMI was 28AE5, and the mean follow up was 47AE45 months. 40% patients had a high ASA score (!3). 6% patients received neoadjuvant chemotherapy. Intracorporeal diversion was adopted in 9% patients and 15% received neobladders. Median operative time was 6.5 hrs with estimated blood loss of 400 ml. Overall complications occurred in 65% and high grade complications were observed in 23%. Distant recurrences were noticed in 27% and local recurrences in 16%. The 10-year DSS (Fig 1a) , and RFS (Fig 1b) for pT2 vs !pT3 rates were 83% vs 45%, and 79% vs 40% respectively. The 10-year DSS (Fig 1d) , and RFS (Fig 1e) , for lymph
